Trials / Completed
CompletedNCT00536809
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
A Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced or Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the highest, tolerated dose level and safety of lapatinib, capecitabine and oxaliplatin in subjects with advanced cancer and to determine the clinical activity of the combination of drugs in subjects with previously untreated advanced or metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lapatinib | onced daily Days 1-21 |
| DRUG | oxaliplatin | Day one of each cycle |
| DRUG | capecitabine | given BID days 1-14 |
Timeline
- Start date
- 2007-09-26
- Primary completion
- 2008-10-31
- Completion
- 2008-10-31
- First posted
- 2007-09-28
- Last updated
- 2017-12-18
- Results posted
- 2010-06-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00536809. Inclusion in this directory is not an endorsement.